Understanding how natural killer cells affect multiple sclerosis
Role of Natural Killer Cell Diversity in Multiple Sclerosis Risk and Disease Course
This study is looking at how certain immune cells called natural killer (NK) cells and their unique features might affect the development and progression of multiple sclerosis (MS), with the hope of finding new ways to understand and manage the condition better for people living with MS.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10707310 on NIH RePORTER |
What this research studies
This research investigates the role of natural killer (NK) cells and their diverse receptors in the development and progression of multiple sclerosis (MS). By analyzing genomic variations of NK cell receptors in well-defined MS patient groups, the study aims to uncover how these variations influence the disease. Advanced sequencing technologies will be employed to gather detailed data on NK cell characteristics and their functional implications in MS. The ultimate goal is to provide insights that could lead to better understanding and management of MS.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with multiple sclerosis who are willing to participate in genetic and immunological assessments.
Not a fit: Patients with other neurological disorders or those without a diagnosis of multiple sclerosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for predicting and treating multiple sclerosis.
How similar studies have performed: Previous research has shown promising results in understanding immune cell roles in autoimmune diseases, suggesting that this approach could yield valuable insights.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Hollenbach, Jill Allison — University of California, San Francisco
- Study coordinator: Hollenbach, Jill Allison
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.